Equity Overview
Price & Market Data
Price: $1.50
Daily Change: +$0.04 / 2.67%
Range: $1.30 - $1.52
Market Cap: $191,689,248
Volume: 1,174,902
Performance Metrics
1 Week: -13.61%
1 Month: 20.66%
3 Months: -18.44%
6 Months: -54.66%
1 Year: -80.32%
YTD: -50.00%
Company Details
Employees: 214
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic therapies to address the spectrum of diseases by deploying gene editing technology in the United States. It offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that copies the edited DNA sequence directly into the target genomic site where the edit is made; and pegRNA which contains a search sequence, also known as a spacer, which provides a target genomic address for the Prime Editor. The company has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. Prime Medicine, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.